Severin Kabakama is a Research Scientist at the Mwanza Intervention Trials Unit (MITU). He is currently coordinating a randomized controlled clinical trial of a social worker intervention designed to reduce post-hospitalization mortality in HIV-infected adults in Mwanza region, Tanzania. Dr Kabakama holds a degree in medicine from the University of Dar es Salaam in Tanzania and a joint degree in public health from the Catholic University of Health and Allied Sciences in Tanzania and University of Calgary in Canada.
Severin comes from the humanitarian health and grants management background, with a specific interest in health systems strengthening, and has previously worked in Tanzania, Zambia, South Sudan, Haiti and Mozambique. His first appointment with MITU was between 2015-2017. During this period, he collated results and lessons learnt from the HPV vaccine demonstration projects and national programmes in low and middle-income countries, and supported the setting up of a trial aimed to determine whether the one and two dose schedules of the 2-valent HPV vaccine (HPV16/18; Cervarix®), and the new 9-valent (HPV6/11/16/18/31/33/45/52/58; Gardasil 9®) vaccine produce immune responses over a 36 month period that are non-inferior to those observed when 3 doses of these vaccines given to girls aged 9-14 years.